Information Provided By:
Fly News Breaks for August 4, 2017
CC
Aug 4, 2017 | 09:11 EDT
JPMorgan analyst Jeffrey Zekauskas upped his price target for Chemours to $55 citing his "sharply raised" earnings and EBITDA estimates following the company's Q2 results. The analyst keeps an Overweight rating on the shares.